SageTherapeutics-JPM2025Presentation

J.P. Morgan Healthcare ConferenceJanuary 2025Sage Therapeutics © 2025Safe Harbor Statement2•The slides presentedtodayand the accompanying oral presentations contain forward-lookingstatements, which may be identifiedby the use ofwords such as “may,” “might,” “will,” “should,”“can,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “opportunity”,“goal”, “mission”, "vision", “potential,” “target”, or “continue,” and other similar expressions.•Forward-looking statements in this presentation include statements regarding: plans, expectations, strategy and goals for commercialization of ZURZUVAE asa treatment for women with PPD, including ourgoal for ZURZUVAE to become first line therapy and standard of care in this indication, plans to scale and accelerate growth of ZURZUVAE in PPD, our plans to increase investment in ZURZUVAE to help accelerate market and topline revenue growth in 2025 and our overall expectations on the impact of such increased investmen